dsm-firmenich has announced its attendance to CPHI 2024.
The nutrition, health and beauty specialist will be located at booth 3B25, and will showcase its range of speciality pharmaceutical ingredients, as well as its optimisation services.
CBtru
According to dsm, the spotlight will be on its novel cannabidiol (CBD) ingredient, CBtru.
CBtru is designed for oral solid dosage forms, and allows higher API loading into a formulation.
It also offers better stability and enhanced pharmacokinetic performance.
The company will also demonstrate how its service programme can address customer concerns in the pharmaceutical industry.
Modulation solutions for better patient compliance
As well as its range of active ingredients, dsm-firmenich will showcase its OSD modulation solutions.
The services are designed to tackle the issue of patient compliance, specifically focusing on making oral dosage forms more palatable.
“Therapies are only effective if adhered to. However, more than 60% of APIs in the market are considered bitter. That’s why, among other challenges, we’re tackling API bitterness head-on,” said dsm-firmenich’s Global Market Development Manager for Pharma Excipients, Fernanda Onofre.
“We have the capabilities to map bitterness receptors and how they interact with APIs, allowing us to develop highly effective and specific bitter blockers. These insights could have a huge impact in galenic forms especially, such as orally disintegrating tables and films and oral liquids, where the formulation components come into direct contact with the tongue.”
Serving the pharmaceutical industry
At CPHI Milan 2024, dsm-firmenich will also be available to discuss its enhanced service programme.
The initiative, powered by dedicated quality, regulatory and sustainability expertise, aims to help drug developers meet regulatory requirements for their market.
“The programme offers several service levels to meet specific customer needs and provides access to our broad portfolio of high-quality pharmaceutical ingredients supported by comprehensive dossiers and global market access,” comments Kelsey Achenbach, Vice President Pharma at dsm-firmenich.
“As one of the only suppliers with EcoVadis Platinum certification, we also help our partners drive innovation with environmental responsibility at its core. This includes providing ingredient-level data and in-house Life Cycle Assessments (LCAs) expertise to help customers achieve their own sustainability targets, including Scope 3 goals.”
